World Health Organization (WHO), Geneva, has included Aurobindo Pharma's one more product - Nevirapine tablets -200 in its pre-qualification list. This is the company's fourth product to be included in the list. The other products included are Zidovudine tablets - 300 mg, Lamivudine tablets - 150 mg & Lamivudine tablets - 300 mg. This is one more milestone for the company, a release said.

Nevirapine is a key ARV in the treatment of AIDS. Nevirapine is in the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which helps keep the AIDS virus from reproducing. This antiretroviral drug is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.

All the four products form part of Anti Retrovirals (ARVs), which help Aids/HIV affected countries to provide cost effective treatment. The global fund to fight AIDS, Tuberculosis and Malaria disburses money for medicines that have been pre-qualified by the WHO process.

Aurobindo Pharma Limited, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa.

The company's robust product portfolio is spread over six major therapeutic /product areas encompassing Antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, and anti-allergics, and around 65 APIs in the non-antibiotics and 55 APIs in the antibiotic segment. The company is marketing these products globally, in over 100 countries.